4. Laboratory assessment of fibrinolysis ‐ Avvisati 1989.
| Coagulation factors | Timing |
Treatment groups Median (range) |
|
| Tranexamic acid | Placebo | ||
| Fibrinogen (mg/dL) | Baseline | 80 (55 to 395) | 70 (50 to 190) |
| Day 3 | 55 (20 to 125) | 62 (45 to 150) | |
| Day 5 | 53 (35 to 80) | 78 (36 to 150) | |
| Day 7 | 60 (50 to 65) | 85 (17 to 160) | |
| Thrombin‐antithrombin complex (ng/mL) | Baseline | 32 (4 to 58) | 22 (15 to 26) |
| Day 3 | 50 (20 to 100) | 22 (11 to 52) | |
| Day 5 | 41 (5 to 51) | 17 (5 to 34) | |
| Day 7 | 10 (5 to 31) | 21 (3 to 37) | |
| α2‐antiplasmin (%) | Baseline | 39 (29 to 80) | 50 (29 to 58) |
| Day 3 | 27 (17 to 40) | 35 (27 to 47) | |
| Day 5 | 32 (27 to 34) | 36 (29 to 51) | |
| Day 7 | 33 (19 to 53) | 42 (32 to 59) | |
| Fibrin/fibrinogen degradation products (μg/dL) | Baseline | 40 (10 to 80) | 80 (40 to 160) |
| Day 3 | NR | NR | |
| Day 5 | NR | NR | |
| Day 7 | NR | NR | |
NR: not reported